Effects of Repeated Electroconvulsive Therapy Sessions on Anesthetic Requirements (REPEAT-ECT)

February 11, 2026 updated by: Murat Kaykaç, Izmir City Hospital

Effects of Repeated Electroconvulsive Therapy on Anesthetic Requirements: A Prospective Observational Study

Electroconvulsive therapy (ECT) is an effective treatment for severe depression and other psychiatric disorders. ECT is usually given in several sessions on different days. During each session, patients receive short-acting anesthesia to ensure comfort and safety.

This study aims to evaluate whether the amount of anesthetic medication required changes during repeated ECT sessions in the same patient. In addition, the study will examine the relationship between anesthetic dose, seizure duration, seizure quality (measured by postictal suppression index), and recovery time.

This is a prospective observational study. All anesthesia and ECT procedures will be performed according to routine clinical practice. No additional intervention will be applied for research purposes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Electroconvulsive therapy (ECT) is a well-established biological treatment for treatment-resistant depression and other affective disorders. Adequate anesthesia is essential to ensure patient safety while maintaining optimal seizure quality and therapeutic efficacy. Short-acting anesthetic agents are commonly used in ECT due to their favorable recovery profiles and hemodynamic stability.

Previous studies suggest that anesthetic requirements may change across repeated ECT sessions, potentially influencing seizure duration, seizure quality, and recovery time. However, evidence regarding within-patient changes in anesthetic dose requirements and their relationship with electroencephalographic seizure characteristics remains limited.

This prospective observational cohort study aims to evaluate changes in anesthetic requirements during repeated ECT sessions in adult patients. Secondary objectives include examining the association between anesthetic dose, seizure duration (motor and EEG), postictal suppression index (PSI), and recovery time.

All ECT and anesthesia procedures will be conducted according to institutional routine clinical protocols. The research team will not interfere with clinical decision-making. Data will be collected from anesthesia records and EEG documentation. Mixed-effects statistical models will be used to account for repeated within-subject measurements.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Murat KAYKAC, Specialist, MD
  • Phone Number: +905330258450
  • Email: mrtkykc@gmail.com

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients aged 18-65 years with an established indication for electroconvulsive therapy (ECT) who are scheduled to undergo multiple ECT sessions at a tertiary care hospital. Participants will be consecutively enrolled during the study period according to eligibility criteria. All procedures will be performed as part of routine clinical care.

Description

Inclusion Criteria:

Age 18 to 65 years.

Scheduled to undergo electroconvulsive therapy (ECT) under elective conditions as part of routine clinical care.

ECT indication (e.g., major depressive disorder, bipolar depression, schizoaffective disorder, catatonia).

ASA Physical Status I-III.

Planned to receive multiple ECT sessions.

Able to provide written informed consent (participant and/or legally authorized representative).

Exclusion Criteria:

Use of antiepileptic drugs or benzodiazepines that may affect seizure threshold.

ECT received within the past 6 months.

Severe cardiovascular, pulmonary, or neurologic comorbidity (investigator judgment).

Pregnancy or breastfeeding.

ASA Physical Status IV or higher.

Acute substance or alcohol use disorder/intoxication.

Conditions preventing EEG monitoring (e.g., scalp trauma, significant skin lesions, cranial implants).

Inability to obtain reliable BIS monitoring during anesthesia induction due to technical limitations.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Adults Undergoing Repeated ECT
Adult patients aged 18-65 years with an indication for electroconvulsive therapy (ECT) who are scheduled to undergo multiple ECT sessions under routine clinical practice. All anesthesia and ECT procedures will be performed according to standard institutional protocols. No additional intervention will be applied for research purposes. Repeated within-subject measurements will be collected across ECT sessions.
Procedure: Electroconvulsive Therapy (ECT)
Electroconvulsive therapy administered as part of routine clinical care. The study does not assign or modify the intervention. Anesthetic management and ECT parameters are determined by treating physicians according to standard institutional protocols.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Anesthetic Dose Requirement Across Repeated ECT Sessions
Time Frame: Across the first 4 ECT sessions per participant (from Session 1 to Session 4), during the study period (up to 3 months).
Dose (mg) of the anesthetic agent administered for each ECT session (e.g., propofol or etomidate), recorded from anesthesia records and analyzed as within-subject change across sequential sessions.
Across the first 4 ECT sessions per participant (from Session 1 to Session 4), during the study period (up to 3 months).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Izmir City Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 18, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025/586

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Electroconvulsive Therapy

Clinical Trials on Electroconvulsive Therapy (ECT)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings